Introduction {#S0001}
============

Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and the fourth leading cause of cancer-related mortality wordwide.[@CIT0001],[@CIT0002] Although surgical resection is still the primary approach for HCC patients, only 30--40% patients are operable, partially due to the factor that majority of HCC patients were diagnosed at the advanced stage.[@CIT0003] Alpha-fetoprotien (AFP) is the most commonly used biomarker for diagnosis of HCC. However, the sensitivity and specificity of AFP are unsatisfied for screening of early-stage HCC.[@CIT0004] Thus, it is imperative to identify novel biomarkers for HCC diagnosis.

Circular RNA (circRNA) is a type of endogenous noncoding RNA with a stable structure formed by special loop splicing.[@CIT0005] It was regarded as non-functional by-products of splicing errors.[@CIT0006] Recently, mainly because of improvement in high-throughput sequencing and bioinformatics, a growing number of circRNAs has been discovered in a number of cancers.[@CIT0007],[@CIT0008] CircRNAs may act as miRNA sponges, protein-binding molecules and templates for translation into polypeptides in the regulation of physiopathology.[@CIT0009]--[@CIT0011] Increasing studies demonstrate that circRNA-mediated networks involved in cell apoptosis, proliferation, cell cycle control and metastasis in cancer.[@CIT0012]--[@CIT0015] Furthermore, circRNAs might also act as potential novel diagnostic and prognostic biomarkers of cancer.[@CIT0016],[@CIT0017]

In the present study, we utilized RNA-sequencing to determine if there were differentially expressed circRNAs in six cases of HCC tissues (three cases with or without portal vein invasion). We found that hsa_circ_0003998 expression in HCC tissues with portal vein invasion was significantly higher than those without portal vein invasion. Hsa_circ_0003998 is a circRNA that is 304nt in spliced sequence length, and its gene is located at chr20: 47570092--47580435. It derives from exons 6 and 7 of the ADP ribosylation factor guanine nucleotide exchange factor 2 (ARFGEF2) gene. Therefore, we determined the relationship between the clinicopathological features or prognosis of HCC.

Patients and methods {#S0002}
====================

Patients and samples {#S0002-S2001}
--------------------

Two hundred paired HCC and adjacent noncancerous tissues were collected from Tongren Hospital, Shanghai Jiao Tong University School of Medicine, People\'s Republic of China from August 2013 to September 2015. At the same time, we collected peripheral blood samples from 100 HCC patients, 50 hepatitis B patients and 50 healthy controls. The blood samples of HCC were collected before surgery and after surgery (more than 21 days after surgery), respectively. Five milliliter blood was obtained from each subject in K2-EDTA tubes and centrifuged at 1600g for 10 mins at 4°C, followed by 12,000g for 10 mins at 4°C. The supernatants (plasma) were collected and stored at −80°C until use. HCC was verified by pathologists for routine diagnosis. The clinical staging was determined by the Barcelona clinic liver cancer staging system. The patients underwent preoperative chemoradiotherapy were excluded. All specimens were stored at −80°C in RNA fixer reagent till use. The study was approved by the Human Ethics Committee of Tongren Hospital, Shanghai Jiao Tong University School of Medicine. The study complied with Declaration of Helsinki and all patients agreed to participate in the study and gave written informed consent.

Cell culture {#S0002-S2002}
------------

The HCC cell lines HepG2, HuH7, MHCC97H, PLC/PRF/5 as well as the immortalized human hepatic cell line L02 were obtained from ATCC. Cells were cultured in DMEM (HyClone, USA) containing 10% fetal bovine serum (Gibco, USA) and 1% penicillin/streptomycin at 37°C in a humidified atmosphere of 5% CO~2~.

Total RNA extraction and reverse transcription {#S0002-S2003}
----------------------------------------------

Total RNA from tissues was extracted by using the Trizol reagent (Invitrogen, USA) according to the instruction from the manufacturer. Total RNA from plasma specimens was extracted by using miRNeasy Mini Kit (Qiagen, German). RNA concentration was measured with a NanoDrop ND-1000 (Thermo Fisher Scientific, Waltham, MA, USA). cDNA was synthesized using PrimeScript^TM^ RT Master Mix (TaKaRa, Dalian, People's Republic of China) according to the manufacturer's protocol (with random primers).

qRT-PCR {#S0002-S2004}
-------

qRT-PCR was performed with SYBR Premix Ex TaqTM II (TaKaRa, Dalian, People's Republic of China) on LightCycler 480II real-time PCR system (Roche) following manufacturer's instructions. The primers used for the PCR reactions were hsa_circ_0003998 (forward: 5ʹ-CAGGAGGTGGTGAAGGACAT-3ʹ and reverse: 5ʹ-CCTGACTGTGCTTCAAACGA-3ʹ) and GAPDH (forward: 5ʹ- GGGAGCCAAAAGGGTCAT-3ʹ and reverse: 5ʹ-GAGTCCTTCCACGATACCAA-3ʹ). These primers were synthesized by Sangon Biotech (Shanghai, People's Republic of China). The data were analyzed using the ΔCt method. All results were expressed as the mean±SD from three repeated experiments.

RNA-seq {#S0002-S2005}
-------

RNA-seq libraries were constructed based on the Illumina standard protocols. Total RNA was treated with RiboMinus Eukaryote Kit (Qiagen, Valencia, CA, USA) to remove ribosomal RNAs, and digested with RNAse R to remove linear RNAs. The enriched circRNAs were prepared by the NEBNext Ultra Directional RNA Library Prep Kit for Illumina (NEB, Beverly, MA, USA) following the Illumina protocol. The main steps involved: the fragmentation of circRNA, second-strand cDNA synthesis, end repair, add an A at the 3ʹ end and ligated to adaptors. The ligated cDNA products were purified and subjected to PCR amplification. The libraries were sequenced on the Illumina HiSeq2500 platform (Illumina,USA) on a 100 bp paired-end run.

Sanger sequencing {#S0002-S2006}
-----------------

qRT-PCR products were inserted into a T vector for Sanger sequencing by determining its full-length by Sangon Biotech (Shanghai, People's Republic of China).

Statistical analyses {#S0002-S2007}
--------------------

All statistical data were analyzed using SPSS 13.0 (SPSS Inc., USA) and GraphPad Prism 5.0 (GraphPad software, USA). The differences in the levels of hsa_circ_0003998 were analyzed by the Student's t-test for paired data. Independent sample *t*-test and one-way (ANOVA were determined correlations between expression levels of hsa_circ_0003998 and clinicopathological factors. The receiver operating characteristic (ROC) curve was generated to evaluate its diagnostic value. The cutoff value was calculated according to Youden's index. Kaplan--Meier analysis with log-rank statistic was used to analyze the overall survival (OS). Independent prognostic factors were performed using the Cox regression model. Two-sided *P*\<0.05 was considered statistically significant.

Results {#S0003}
=======

Overview of circRNA profiles in HCC tissues {#S0003-S2001}
-------------------------------------------

It was obtained that circRNA profiles from six cases of HCC tissues (three cases with or without portal vein invasion) ([Table S1](#ST0001)). Hierarchical clustering demonstrated the distributions of circRNA profiles ([Figure 1](#F0001){ref-type="fig"}). Overall, 121 circRNAs were co-expressed, including 14 upregulated and 8 downregulated circRNAs in HCC tissues with portal vein invasion compared to those without portal vein invasion. Among them, the most prominent circRNA was hsa_circ_0003998.Figure 1Overview of the RNA-seq signatures.**Notes:** Hierarchical clustering analysis showed distinguishable circRNA profiles among HCC tissues with or without portal vein invasion (high: with portal vein invasion, low: without portal vein invasion). Yellow indicated higher expression level and purple indicated lower expression level. The red arrow stands for hsa_circ_0003998.**Abbreviation:** HCC, hepatocellular carcinoma.

Hsa_circ_0003998 was up-regulated in HCC tissues and cells {#S0003-S2002}
----------------------------------------------------------

It was measured the expression of hsa_circ_0003998 in 200 paired human HCC and adjacent noncancerous tissues and HCC cell lines using qRT-PCR. The specificity of products was confirmed using electrophoresis ([Figure 2A](#F0002){ref-type="fig"}). The accuracy was confirmed by Sanger sequencing ([Figure 2B](#F0002){ref-type="fig"}). Hsa_circ_0003998 was up-regulated in HCC tissues (*P*\<0.001) ([Figure 2C](#F0002){ref-type="fig"}) and HCC cell lines (HepG2, HuH7, MHCC97H) (*P*\<0.001) ([Figure 2D](#F0002){ref-type="fig"}) .Figure 2hsa_circ_0003998 expression features. (**A**) Electrophoresis of qRT-PCR products. Lane M is DL2000 Marker, lanes 1--5 are products. (**B**) Validation of splicing junction site through sequencing of qRT-PCR products. (**C**) High levels of hsa_circ_0003998 in HCC tissues (n=200, *P*\<0.001). (**D**) High levels of hsa_circ_0003998 in HCC cell lines. The △Ct value was determined by subtracting the Ct value of GAPDH from the Ct value of hsa_circ_0003998. Larger ΔCt value indicated lower level. \*\**P*\<0.001 represented the statistical differences.

Correlations between hsa_circ_0003998 levels and clinicopathological factors in HCC patients {#S0003-S2003}
--------------------------------------------------------------------------------------------

It was analyzed that the association between hsa_circ_0003998 levels and clinicopathological factors of HCC patients. As shown in [Table 1](#T0002){ref-type="table"}, upregulation of hsa_circ_0003998 level was significantly correlated with higher serum AFP level (*P*=0.003), larger tumor diameter (*P*=0.009), microvascular invasion (MVI) (*P*=0.028) and lower differentiation level (*P*=0.023).Table 1The relationship between hsa_circ_0003998 expression levels (△Ct) and clinical characteristics of HCC patientsCharacteristicsPatient number (total=200)Mean±SD*P*-valueGender Male1087.6±1.590.077 Female928.01±1.68Age (years) ≤60917.73±1.630.678 \>601097.83±1.66HCC history Negative1767.82±1.840.474 Positive247.56±1.84Smoking Negative1407.85±1.570.384 Positive607.63±1.8Alcoholism Negative1347.89±1.520.213 Positive667.56±1.87HBsAg Negative528.08±1.630.135 Positive1487.68±1.64Anti-HCV Negative1947.8±1.660.368 Positive67.19±1.13AFP ≥400 ng/mL1327.55±1.7**0.003** \<400 ng/mL688.24±1.44Child-Pugh classification Child-Pugh A1687.82±1.650.528 Child-Pugh B327.62±1.6Tumor diameter ≥5 cm1427.61±1.72**0.009** \<5 cm588.22±1.36TNM I/II1317.92±1.560.14 III/IV697.54±1.78MVI Positive487.33±1.8**0.028** Negative1527.93±1.57Differentiation High/moderate1357.98±1.48**0.023** Low657.37±1.89BCLC stage Stage A1027.76±1.750.95 Stage B627.84±1.42 Stage C367.76±1.73ALT ≥50 U/L757.74±1.660.766 \<50 U/L1257.81±1.64AST ≥40 U/L607.73±1.790.748 \<40 U/L1407.81±1.58Liver cirrhosis Yes1227.66±1.710.191 No787.98±1.52[^2][^3]

Potential diagnostic values of hsa_circ_0003998 {#S0003-S2004}
-----------------------------------------------

ROC curves were used to determine the diagnostic value of hsa_circ_0003998 in distinguishing HCC from adjacent noncancerous tissues. It was observed that the area under the ROC curve (AUC) was 0.894 (95% CI=0.86--0.922, *P*\<0.001, [Figure 3A](#F0003){ref-type="fig"}). The sensitivity and specificity were 0.84 and 0.8, respectively. The value of the cutoff was 9.205.

The plasma level of hsa_circ_0003998 in postoperative patients was significantly decreased than those in preoperative patients (post vs pre: 10.79±0.97 vs 10.21±1.2, *P*\<0.001) ([Figure 3B](#F0003){ref-type="fig"}). The plasma level of hsa_circ_0003998 in HCC patients was significantly higher than those in hepatitis B patients (*P*\<0.001) and healthy controls (*P*\<0.001) ([Figure 3C](#F0003){ref-type="fig"}). ROC curve showed that, comparing with hepatitis B patients and healthy controls, hsa_circ_0003998, respectively, had an AUC value of 0.833 (95% CI=0.763--0.889, *P*\<0.001) ([Figure 3D](#F0003){ref-type="fig"}) and 0.892 (95% CI=0.831--0.937, *P*\<0.001) ([Figure 3E](#F0003){ref-type="fig"}). Besides, their sensitivity and specificity were 0.83, 0.7 and 0.8, 0.84, respectively. The values of cutoff were 11.345 and 11.255, respectively. Moreover, the combination of hsa_circ_0003998 and AFP for discriminating between HCC and healthy controls showed the highest AUC value of 0.947 (95% CI=0.898--0.977, *P*\<0.001)([Figure 3F](#F0003){ref-type="fig"}). The sensitivity and specificity were 0.88 and 0.92, respectively.Figure 3hsa_circ_0003998 as a biomarker. (**A**) ROC curves of hsa_circ_0003998 for discriminating between HCC and noncancerous tissues (*P*\<0.001). (**B**) The plasma levels of hsa_circ_0003998 in preoperative and postoperative patients (*P*\<0.001). (**C**) The plasma levels of hsa_circ_0003998 in HCC, hepatitis B patients and healthy controls (*P*\<0.001). (**D**) ROC curves of hsa_circ_0003998 for discriminating between HCC and hepatitis B patients (*P*\<0.001). (**E**) ROC curves of hsa_circ_0003998 for discriminating between HCC and healthy controls (*P*\<0.001). (F) ROC curves of combination of hsa_circ_0003998 and AFP for discriminating between HCC and healthy controls (*P*\<0.001). \*\**P*\<0.001 represented the statistical differences.**Abbreviations:** ROC, receiver operating characteristic; HCC, hepatocellular carcinoma; AFP, alpha-fetoprotien.

Potential prognostic values of hsa_circ_0003998 {#S0003-S2005}
-----------------------------------------------

The HCC patients were divided into high (n=100) and low (n=100) expression groups according to the median level of hsa_circ_0003998 (ΔCt=8.235) in HCC tissues. Kaplan--Meier survival curves revealed that high hsa_circ_0003998 expression was significantly correlated with poor OS(*P=*0.005, [Figure 4](#F0004){ref-type="fig"}).Figure 4The overall survival analysis in HCC patients by Kaplan--Meier method (*P=*0.005).**Abbreviation:** HCC, hepatocellular carcinoma.

On univariate analysis, AFP (*P*=0.013), TNM stage (*P*=0.044) and hsa_circ_0003998 expression (*P*=0.006) were correlated with poor OS in HCC patients ([Table 2](#T0003){ref-type="table"}). Furthermore, Cox multivariate analysis revealed that hsa_circ_0003998 (*P*=0.003) and AFP (*P*=0.008) were the independent prognostic factors for poor OS ([Table 2](#T0003){ref-type="table"}).Table 2Univariate and multivariate analyses of various prognostic parameters in HCCParametersRegression coefficient *β*HR (95% CI)*P-*valueUnivariate analysisGender−0.3090.734 (0.513--1.05)0.091Age−0.0260.974 (0.682--1.391)0.885Smoking0.2121.237 (0.845--1.81)0.274Alcoholism0.0251.025 (0.702--1.496)0.898HBsAg−0.0030.997 (0.668--1.486)0.997AFP0.51.648 (1.112--2.444)**0.013**Tumor diameter0.2861.331 (0.889--1.993)0.165TNM0.3741.454 (1.01--2.093)**0.044**Differentiation0.3061.359 (0.938--1.967)0.105BCLC stage−0.0390.962 (0.76--1.218)0.747ALT0.0521.053 (0.732--1.514)0.781AST0.1911.21 (0.827--1.771)0.326Liver cirrhosis0.2321.261 (0.871--1.826)0.22Hsa_circ_0003998 expression−0.5050.604 (0.422--0.864)**0.006**Multivariate analysisAFP0.5381.713 (1.153--2.544)**0.008**Hsa_circ_0003998 expression−0.5390.583 (0.407--0.836)**0.003**[^4][^5]

Discussion {#S0004}
==========

HCC is the sixth high morbidity and the fourth leading cause of cancer mortality worldwide.[@CIT0002] HCC is accounted for 80--90% cases of liver cancer. It is rather distressed that the majority of HCC patients are diagnosed at advanced stages, missing the opportunity for curative treatment.[@CIT0018] Therefore, it is imperative to discover novel tumor markers for early diagnosis of HCC.

Recent reports revealed that the imbalanced expression of circRNAs is common in tumor and played crucial roles in biological processes.[@CIT0019] Moreover, it is suggested that circRNA might act as a potential diagnostic and prognostic biomarker in HCC.[@CIT0020],[@CIT0021] For example, it has been found that hsa_circ_0005075 has diagnostic value in HCC (AUC=0.94).[@CIT0022] Currently looking for a diagnostic target for HCC has become a hot spot for researchers Downregulation of hsa_circ_0001445 in HCC is correlated with tumor differentiation, tumor stage and MVI, and considered as a risk factor for OS and recurrence-free survival.[@CIT0023]

In the current study, circRNA profiles screened by RNA-seq showed that hsa_circ_0003998 was significantly higher in HCC tissues with portal vein invasion than in HCC tissues without portal vein invasion. HCC has the characteristics of easy invasion and metastasis, which are the critical factors of high recurrence rate and poor prognosis.[@CIT0024] To explore the possible effect of hsa_circ_0003998 in HCC, we found that it was significantly higher in HCC tissues than in adjacent noncancerous tissues (*P*\<0.001). Moreover, hsa_circ_0003998 level was significantly higher in HCC cell lines than in human hepatic cell line (*P*\<0.001). Collectively, these findings demonstrated that hsa_circ_0003998 was significantly upregulated in HCC.

We also found that upregulation of hsa_circ_0003998 level was significantly associated with higher serum AFP level, larger tumor diameter, lower differentiation level and MVI. The plasma level of hsa_circ_0003998 in HCC patients was significantly higher than those in hepatitis B patients and healthy controls. Besides, the plasma level of hsa_circ_0003998 was significantly reduced after operation. The phenomenon might be due to the decreasing release of tumor-derived nucleic acid after tumor excision. The results suggest that hsa_circ_0003998 plays an important role during tumorigenesis of HCC.

The early diagnosis of HCC is of paramount importance for good prognosis. Currently, combination of radiology and serum AFP levels fail to diagnose HCC at the early stage.[@CIT0025] Therefore, it is urgent to recognize efficient molecular markers for HCC diagnosis. CircRNAs are endogenous, conserved, abundant and steady in cells, and are related to carcinomas.[@CIT0026] Moreover, in comparison to their cognate linear isoforms, the expression levels of circRNAs are above 10 fold.[@CIT0027] They were appealed as molecular biomarkers for cancer diagnosis and monitoring. The ROC analysis showed that AUC was 0.894, sensitivity and specificity were 0.84 and 0.8 for distinguishing HCC from adjacent noncancerous tissues. Comparing with healthy controls, hsa_circ_0003998 had an AUC value of 0.892, the sensitivity and specificity were 0.8 and 0.84, respectively. Moreover, the combination of hsa_circ_0003998 and AFP showed the highest AUC value of 0.947, the sensitivity and specificity were 0.88 and 0.92, respectively. Thus, hsa_circ_0003998 was recognized as a novel biomarker for distinguishing HCC from non-HCC with favorable sensitivity and specificity.

KaplanMeier analysis suggests that HCC patients with high level of hsa_circ_0003998 had significantly shorter OS than those with low level. Moreover, the Cox regression suggests that hsa_circ_0003998 was the independent favorable predictor of OS in HCC patients, but the functions of circRNAs in carcinogenesis and tumor progression remain to be elucidated clearly. Increasing evidence suggests that circRNA regulates tumor progression via acting as a miRNA sponge or regulating the expression of parental gene.[@CIT0009],[@CIT0028],[@CIT0029] This is supported by the finding that circ-ITCH could function as miR-17 and miR-224 sponges and regulate p21 and PTEN genes to suppress aggressive biological behaviors of bladder cancer.[@CIT0030] CircMTO1 may also sponge miR-9 and inhibit its oncogenic effect with circMTO1/miR-9/p21 axis in HCC.[@CIT0016] Using bioinformatics program (Circular RNA Interactome, <https://circinteractome.nia.nih.gov/index.html>), it is discovered that miR-1184, miR-1243, miR-136, miR-145, miR-197, miR-326, miR-330-5p, miR-513a-5p, miR-576-3p and miR-636 are the potential binding targets of hsa_circ_0003998 ([Figure 5](#F0005){ref-type="fig"}). This is in line with the findings form Yu et al[@CIT0031] that hsa_circ_0003998 acts as an oncogene in non-small cell lung cancer by modulating miR-326/Notch1. Such data suggest that hsa_circ_0003998 plays an important role through sponging miRNA in HCC, which may provide a direction for future study to explore the precise mechanism of hsa_circ_0003998 in carcinogenesis of HCC both in vivo and in vitro.Figure 5TargetScan miRNA predictions.

Conclusion {#S0005}
==========

In summary, hsa_circ_0003998 was expressed higher in HCC compared to the non-HCC. Hsa_circ_0003998 correlated with AFP, tumor diameter, differentiation and MVI might be used as a novel potential biomarker for early diagnosis and prognosis of HCC patients.
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Table S1The patient profiles of HCC samples for RNA-sequencingCharacteristicsPortal vein invasion (n=3)Without portal vein invasion (n=3)Gender Male22 Female11Age (years) ≤6033 \>6000HCC history Negative33 Positive00HBsAg Negative01Positive32Anti-HCV Negative33 Positive00AFP ≥400 ng/mL33 \<400 ng/mL00Child-Pugh classification Child-Pugh A11 Child-Pugh B22Tumor diameter ≥5 cm22 \<5 cm11TNM I/II11 III/IV22Differentiation High/moderate12 Low21BCLC stage Stage A00 Stage B02 Stage C31[^6]

[^1]: These authors contributed equally to this work

[^2]: **Note:** Bold values indicate *P*\<0.05.

[^3]: **Abbreviations:** HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; HCV: hepatitis C virus; AFP, alpha-fetoprotien; MVI, microvascular invasion; BCLC, Barcelona clinic liver cancer; ALT, alanine aminotransferase; AST, aspartate transaminase.

[^4]: **Note:**Bold values indicate *P*\<0.05.

[^5]: **Abbreviations:** HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; AFP, alpha-fetoprotien; BCLC, Barcelona clinic liver cancer; ALT, alanine aminotransferase; AST, aspartate transaminase; HR, hazard ratios; CI, confidence interval.

[^6]: **Abbreviations:** HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; BCLC, Barcelona clinic liver cancer; AFP, alpha-fetoprotien.
